NB1

Bone Biologics Reports Progress With NB1 Clinical Program

Retrieved on: 
Friday, March 1, 2024
Health, Stem Cells, Other Science, Clinical Trials, Research, Science, Biotechnology, Division, Spinal fusion, Degenerative disc disease, Safety, NB1, Patient, DDD, Pharmaceutical industry

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.
  • Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical trial.
  • This pilot clinical trial will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).
  • The study design was previously reviewed and agreed upon by the Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States.

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, General Health, Health, Medical Devices, Disability, ISO, DBM, Quality of life, Degenerative disc disease, Toxicity, NB1, CGMP, Bharat Immunologicals and Biologicals Corporation, Engineering, Hematology, PH, Safety, Pharmaceutical industry

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
  • NB1 consists of the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM).
  • Similar recombinant human NELL-1 (rhNELL-1) drug substance attributes were demonstrated between different rhNELL-1 lots and the cGMP drug substance lot.
  • Mr. Frelick added, “We believe NB1 is poised to address the problems with existing bone growth products by providing rapid, controlled and guided bone growth only in the presence of existing bone.

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Retrieved on: 
Tuesday, April 11, 2023
Research, Medical Devices, Surgery, Clinical Trials, Other Health, Biotechnology, General Health, Health, Science, Other Science, Human, Low back pain, Sleep, Degenerative disc disease, Trial of the century, NB1, Patient, DDD, Bharat Immunologicals and Biologicals Corporation, Food, Safety, Pharmaceutical industry

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC) has approved Monash Health as the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia.
  • This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).
  • Inclusion criteria include patients with DDD at one level from L2-S1 who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level.
  • Bone Biologics previously announced the engagement of Avania as the contract research organization for this pilot clinical trial with NB1.

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Retrieved on: 
Thursday, January 26, 2023
Biotechnology, Surgery, Medical Devices, Health, Clinical Trials, Spinal fusion, Safety, Bharat Immunologicals and Biologicals Corporation, Patient, Degenerative disc disease, NB1, Medical imaging

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1.
  • Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products.
  • The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB1 in patients with degenerative disc disease undergoing a Transforaminal Lumbar Interbody Fusion (TLIF) procedure.
  • This multicenter, parallel group, randomized trial is designed to evaluate the safety and preliminary effectiveness of NB1 bone graft in 30 subjects with degenerative disc disease undergoing a TLIF.

Bone Biologics CEO Issues Letter to Stockholders

Retrieved on: 
Tuesday, October 25, 2022
General Health, Health, Surgery, Other Health, Sheep, Spinal stenosis, Caregiver, Cell bank, Technology, Deformity, NB1, Bharat Immunologicals and Biologicals Corporation, Review, B cell, Technology transfer, CGMP, NASDAQ, Patient, Osteoporosis, Spondylolisthesis, Allotransplantation, Oswestry Disability Index, Degenerative disc disease, UCLA, Publication, Trial of the century, Spinal fusion, CDMO, Trauma, Safety, Letter, DBM, Clinical trial, Environment, Gold standard, MTF, Human, Vaccine, Pharmaceutical industry, Fine chemical, Medical device

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.
  • This potential lies in its ability to provide rapid, specific and guided control over bone regeneration.
  • This is the market Bone Biologics intends to address.
  • We believe our effort will be well-rewarded not only by patients, but also by caregivers and Bone Biologics stockholders.

Quectel Launches Connectivity-as-a-Service and Integrated SIM to Simplify IoT Deployments in Asia Pacific

Retrieved on: 
Wednesday, June 29, 2022
IOT (Internet of Things), Technology, Mobile, Wireless, Telecommunications, Networks, Internet, Tier 1, CAAS, EMEA, Adoption, APAC, Multimedia, Industry, ESIM, Shanghai Stock Exchange, OTA, Global Connectivity Index, ISIM, Risk, SIM, GNSS, Â, Solution, SLA, ANZ, IOT, NB2, GL, NB1, Mobile phone, Cable television

Adding connectivity broadens the Companys portfolio and helps its customers to simplify the journey of designing, building, connecting and commercializing their IoT offerings.

Key Points: 
  • Adding connectivity broadens the Companys portfolio and helps its customers to simplify the journey of designing, building, connecting and commercializing their IoT offerings.
  • View the full release here: https://www.businesswire.com/news/home/20220628006064/en/
    Quectel launches Connectivity-as-a-Service and integrated SIM to simplify IoT deployments in Asia Pacific (Photo: Business Wire)
    Quectel connectivity is available now in more than 190 countries via over 500 network operators, and currently provides 2G, 3G, 4G, NB-IoT and Cat-M connections.
  • Embedded and integrated SIM (eSIM and iSIM) offerings are now entering mainstream adoption, and Quectel has recently launched the new BG773A-GL ultra-compact LTE Cat M1, NB1 and NB2 module which offers integrated SIM (iSIM) support.
  • Quectel is committed to innovation that drives benefits for customers in the IoT industry, and our connectivity launch in the Asia Pacific region is another milestone in that journey.

Quectel powers global connectivity and flexible deployment models with new iSIM-enabled module

Retrieved on: 
Tuesday, June 21, 2022
Telecommunications, Networks, Hardware, Technology, IOT (Internet of Things), Semiconductor, Mobile, Wireless, Security, Solution, RAM, ISIM, ISE, Integration, SIM, Technology, MIPS, CEO, Â, NB2, Shanghai Stock Exchange, Knowledge, Global Connectivity Index, Adoption, GNSS, POS, 5150, Ecosystem, GL, Embedded, NB1, SMT, Multimedia, PSM, Organization, Original equipment manufacturer, SKU, Mobile phone, IOT

Quectel Wireless Solutions has launched the new BG773A-GL ultra-compact LTE Cat M1, NB1 and NB2 module which offers integrated SIM (iSIM) support.

Key Points: 
  • Quectel Wireless Solutions has launched the new BG773A-GL ultra-compact LTE Cat M1, NB1 and NB2 module which offers integrated SIM (iSIM) support.
  • Were delighted to have launched the Quectel BG773A-GL module which brings iSIM-enabled connectivity to the global marketplace, says Richard Hart, Director of Global Connectivity, Quectel Connectivity Solutions .
  • Quectel has collaborated with Kigen , the iSIM pioneer and global security leader to enable the iSIM functionality on BG773A-GL.
  • Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity.